País: Israel
Língua: inglês
Origem: Ministry of Health
REMIFENTANIL AS HYDROCHLORIDE
PADAGIS ISRAEL AGENCIES LTD, ISRAEL
N01AH06
POWDER FOR CONCENTRATE FOR SOLUTION FOR INJECTION / INFUSION
REMIFENTANIL AS HYDROCHLORIDE 5 MG/VIAL
I.V
Required
GLAXO SMITHKLINE MANUFACTURING S.P.A., ITALY
REMIFENTANIL
REMIFENTANIL
Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.
2022-12-31
1 _ _ ראורבפ 2019 ,ה/דבכנ ת/חקור ה/אפור ירבה דרשמ ולעב םיאבה םינוכדעה תא רשיא תוא ן רישכתה םי : ULTIVA 2MG ULTIVA 1MG ULTIVA 5MG הויטלוא 1 ג"מ הויטלוא 2 ג"מ יטלוא ו ה 5 ג"מ ליעפ רמוח : Remifentanil ( as hydrochloride ) 1mg/vial, 2mg/vial, 5mg/vial -------------------------------------------------------------------------------------- :םושירה תדועתב הרשואש יפכ היוותה Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision . Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over. ולעש עידוהל וננוצרב ן רישכתה םי ודנה םינ כדוע ן .הטמ םיטרופמה םיפיעסב וז העדוהב םיניוצמ .יתוהמ יוניש וא הרמחה םיווהמ רשא םייוניש קר בוהצ עקרב םינמוסמו הרמחה םיווהמ םניאש םיפסונ םייוניש ועצוב ןולעב . ל ןולעה אפור רבעוה רשמ לש טנרטניאה רתאבש תופורתה רגאמב םוסרפל תואירבה ד http://www.health.gov.il ,לארשי וגירפ תרבחל הינפ י"ע ספדומ ולבקל ןתינו :ןופלטב 03-5773700 . ,הכרבב מ"עב תויונכוס לארשי וגירפ 2 _ _ ה ןלהל םינוכדע םיירקיעה ל ןולעב אפור : 3. PHARMACEUTICAL FORM Lyophilised powder for reconstitution for solution for intravenousfor intravenous (IV) administration. Ultiva is a sterile, non-pyrogenicendotoxin-free, preservative-free, white to off white, Lyophilised powder, to be reconstituted before use. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE …… RISK FROM CONCOMITANT USE OF SEDATIVE MEDICINES SUCH AS BENZODIAZEPINES OR RELATED DRUGS Concomitant use of Ultiva and sedative medicines such as benzodiazepines or related drugs may result in sedation, r Leia o documento completo
1 _ _ SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ULTIVA 5 MG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION When reconstituted as directed, solutions of Ultiva are clear and colourless and contain 1 mg/ml of remifentanil base as remifentanil hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion. Ultiva is a sterile, non-pyrogenic, preservative-free, white to off white, lyophilised powder, to be reconstituted before use. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision. Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ULTIVA SHOULD BE ADMINISTERED ONLY IN A SETTING FULLY EQUIPPED FOR THE MONITORING AND SUPPORT OF RESPIRATORY AND CARDIOVASCULAR FUNCTION AND BY PERSONS SPECIFICALLY TRAINED IN THE USE OF ANAESTHETIC DRUGS AND THE RECOGNITION AND MANAGEMENT OF THE EXPECTED ADVERSE EFFECTS OF POTENT OPIOIDS, INCLUDING RESPIRATORY AND CARDIAC RESUSCITATION. SUCH TRAINING MUST INCLUDE THE ESTABLISHMENT AND MAINTENANCE OF A PATENT AIRWAY AND ASSISTED VENTILATION. Continuous infusions of Ultiva must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space ( _see section 6.6_ for additional information, including WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death [see sections 4.4 and 4.5]. Reserve concomitant prescribing of these drugs for use in patients for whom Leia o documento completo